Key facts
- ArkeaBio’s last known valuation is $71.0M (Dec 2025).
- It has raised $45.5M; the latest was Early Stage VC ($7.0M) in Dec 2025.
- Notable investors include Breakthrough Energy, The Grantham Foundation, Rabo Investments, AgriZeroNZ, NYA Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for ArkeaBio
- ·The full record, as it builds
Funding rounds
No funding rounds for ArkeaBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ArkeaBio
Developer of a vaccine technology designed to reduce greenhouse gas emissions from the agricultural sector. The company's technology specializes in proven delivery systems and farming practices that safely reduce global methane emissions from multiple ruminant species across a variety of geographies and agronomic systems by neutralizing methane-producing microbes in the animals, enabling companies to eliminate the on-farm methane emissions from livestock, making it a more environmentally friendly and sustainable option for the agriculture industry.
- Sector
- Materials and Resources
- HQ
- Charlestown, MA, United States
- Founded
- 2021
- Employees
- 40
- Website
- arkeabio.com/
- Ownership
- Privately Held (backing)
ArkeaBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ArkeaBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ArkeaBio in its N-PORT filings yet. We sweep new filings monthly.